NeoThy™ immune-humanized mice can produce anti-drug antibodies to support immunogenicity assessment for biological drug products. [PDF]
Gharaie S +10 more
europepmc +1 more source
A prospective study of 150 outpatients with moderate‐to‐severe UC initiating treatment. IUS is performed at baseline, day‐2, ‐7, ‐90 and week 52 alongside clinical, biochemical, endoscopic, patient‐reported and exploratory multiomics assessments. The primary endpoint evaluates whether early change in BWT predicts treatment escalation within 3 and 12 ...
Sabrina Josefsen +6 more
wiley +1 more source
Bridging the Gap Between Chemiluminescence Immunoassay and Liquid Chromatography-Tandem Mass Spectrometry for Infliximab Monitoring: Method Validation and Clinical Comparability Study. [PDF]
Xia Y +8 more
europepmc +1 more source
10 Years Since the LIR!C Trial: Old News or New Beginnings?
ABSTRACT In many patients with Crohn's disease, disease is initially confined to the ileocaecal region. The landmark LIR!C trial published in 2017 demonstrated that in localised ileocaecal disease refractory to standard immunomodulating therapy, primary ileocaecal resection led to similar outcomes concerning quality of life and remission as therapy ...
Paul Griebel
wiley +1 more source
Sex Differences in Growth Recovery among Children with Crohn's Disease. [PDF]
Kim DU +19 more
europepmc +1 more source
Stability of infliximab serum concentrations during long-term frozen storage: a paired biobank study. [PDF]
Anjie SI +4 more
europepmc +1 more source
Enhancing Bioavailability of Ultra-High Concentration Antibody Formulations Using Ionic Liquids. [PDF]
Ramesh A +5 more
europepmc +1 more source
Comparative effectiveness of adalimumab versus infliximab in children with Crohn's disease: real-world data from the prospective PIBD-SETQuality inception cohort study. [PDF]
Vuijk SA +14 more
europepmc +1 more source

